PortfoliosLab logo
Immunovant, Inc. (IMVT)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US45258J1025

CUSIP

45258J102

IPO Date

Jun 21, 2019

Highlights

Market Cap

$2.59B

EPS (TTM)

-$2.62

Gross Profit (TTM)

-$80.00K

EBITDA (TTM)

-$320.73M

Year Range

$12.72 - $34.47

Target Price

$45.15

Short %

23.81%

Short Ratio

7.81

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Immunovant, Inc. (IMVT) returned -43.40% year-to-date (YTD) and -52.79% over the past 12 months.


IMVT

YTD

-43.40%

1M

-5.91%

6M

-54.26%

1Y

-52.79%

5Y*

-7.10%

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.77%

1M

3.72%

6M

-5.60%

1Y

8.55%

5Y*

14.11%

10Y*

10.45%

*Annualized

Monthly Returns

The table below presents the monthly returns of IMVT, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-12.23%-5.24%-17.04%-5.50%-13.19%-43.40%
2024-13.58%-2.86%-8.65%-15.07%-7.47%3.98%10.11%6.30%-7.73%2.63%-3.62%-12.16%-41.21%
20230.11%-1.69%-11.22%4.06%30.17%-9.71%20.35%-0.53%69.04%-13.91%18.40%7.67%137.35%
2022-17.96%-20.17%-1.25%-16.33%-8.03%-8.02%5.64%25.00%8.35%100.72%17.05%35.39%108.33%
2021-15.50%-59.57%1.65%-2.24%-3.32%-30.28%-1.04%-17.21%0.35%-7.48%-4.23%10.65%-81.55%
2020-0.50%-0.38%-1.05%19.24%38.25%-5.11%-7.15%50.20%3.62%23.96%12.77%-6.10%191.05%
2019-1.51%-0.10%1.12%1.21%1.40%2.85%51.87%59.50%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of IMVT is 6, meaning it’s performing worse than 94% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of IMVT is 66
Overall Rank
The Sharpe Ratio Rank of IMVT is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of IMVT is 66
Sortino Ratio Rank
The Omega Ratio Rank of IMVT is 88
Omega Ratio Rank
The Calmar Ratio Rank of IMVT is 99
Calmar Ratio Rank
The Martin Ratio Rank of IMVT is 22
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Immunovant, Inc. (IMVT) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Immunovant, Inc. Sharpe ratios as of May 10, 2025 (values are recalculated daily):

  • 1-Year: -1.01
  • 5-Year: -0.09
  • All Time: 0.08

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Immunovant, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Immunovant, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Immunovant, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Immunovant, Inc. was 93.59%, occurring on Jun 16, 2022. The portfolio has not yet recovered.

The current Immunovant, Inc. drawdown is 73.40%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-93.59%Nov 18, 2020397Jun 16, 2022
-51.2%Jan 17, 202042Mar 18, 202018Apr 14, 202060
-20.5%Jun 24, 202027Jul 31, 202013Aug 19, 202040
-17.39%May 12, 20206May 19, 20204May 26, 202010
-13.21%Sep 17, 20205Sep 23, 202011Oct 8, 202016

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Immunovant, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Immunovant, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -1.0%.


-0.80-0.70-0.60-0.50-0.40-0.30AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
-0.76
-0.75
Actual
Estimate

Valuation

The Valuation section provides an overview of how Immunovant, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for IMVT relative to other companies in the Biotechnology industry. Currently, IMVT has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for IMVT in comparison with other companies in the Biotechnology industry. Currently, IMVT has a P/B value of 7.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items